TheraRadar
← Back
Data updated: Jul 17, 2026

LANNETT CO INC

Generics

LANNETT CO INC is a generic drug manufacturer focused on Infectious Disease, Gastroenterology, Cardiovascular.

1955
Since
103
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
1 Small Molecules

LANNETT CO INC's Key Drugs

LANNETT CO INC's core commercial portfolio centers on BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, LOPINAVIR AND RITONAVIR, spanning Infectious Disease and Gastroenterology — its most strategically important drugs approved in the last 15 years.

LANNETT CO INC's Therapeutic Areas

LANNETT CO INC's approved drugs and pipeline span 5 therapeutic areas, led by Infectious Disease and Gastroenterology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Infectious Disease 28%
6 drugs
Gastroenterology 24%
5 drugs
Cardiovascular 24%
5 drugs
Neurology 14%
3 drugs
Metabolic 10%
2 drugs Phase 1: 1

LANNETT CO INC's Top Competitors

LANNETT CO INC's closest competitors by therapeutic-area and drug-target overlap include Merck, Novo Nordisk, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

LANNETT CO INC Pipeline Snapshot

LANNETT CO INC has 1 active clinical program from ClinicalTrials.gov — 0 Phase 3, 0 Phase 2 and 1 Phase 1.

0
Phase 3
0
Phase 2
1
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE leads revenue
  • 2 key drugs tracked

Trial Catalysts

  • Infectious Disease pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling